25X10 Blister

Levocetrizine is third generation non-sedative antihistamine. It is derived from second generation cetirizine. It is levo form of cetirizine which belongs to second generation. It causes blocking of histamine receptors and prevents the binding of its receptors. In other words it prevents the release of allergic chemicals and decreased the supply of blood to that area.

• Seasonal allergic rhinitis
• Perennial rhinitis
• Chronic idiopathic urticaria

It competes with histamine for binding at H1 receptor on the effectors cell surface which causes the suppression histaminic edema and pruritus. The low incidence of sedation is because the reduced penetration of cetrizine into CNS.

Absorption

It is well absorbed in the body with mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours

Distribution

It is well distributed in the body with 93% plasma protein binding. Vd is 0.41kg

Excretion

 The plasma half life is 7.9 ± 1.9 hours; total body clearance is 0.63 ml/min/kg

• Patients with hypersensitivity to such drugs
• Renal disease
• Pediatric patients with renal impairment

• Long treatment can cause somnolence, fatigue, and asthenia
• Patient should not involved in those task which require complete concentration
• Patients with predisposing factors of urinary retention
• Use in pregnant patients when clearly needed